Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in Metastatic Colorectal Cancer
NCT02204332Phase 2Terminated
- Sponsor
- Complejo Hospitalario Universitario de Santiago
- Start
- Mar 2013
- Primary completion
- Sep 2013
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic colorectal cancer (mCRC) comparing Cabazitaxel with Best Supportive Care (2 arms). Primary endpoint: Overall Response Rate up to 24 months. Started Mar 2013; status: terminated.
02
Drugs
cabazitaxel
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02204332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204332.